Steven Rosenberg

Steven Rosenberg is the father of adoptive cell transfer immunotherapy, having pioneered tumor-infiltrating lymphocyte (TIL) therapy and high-dose IL-2 immunotherapy for melanoma, achieving the first durable complete responses to immunotherapy in metastatic solid tumors and proving that the immune system can completely eradicate established metastatic cancer. His development of high-dose IL-2, the first immunotherapy approved by the FDA for cancer, and TIL therapy, which achieves durable complete responses in approximately 25 percent of metastatic melanoma patients, established the paradigm of cellular immunotherapy. He has treated more cancer patients with immunotherapy than anyone in history. His career spanning five decades has been the driving force behind cancer immunotherapy from laboratory concept to clinical reality.